Patents Examined by Joseph R. Kosack
  • Patent number: 11453668
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 27, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • Patent number: 11453687
    Abstract: A production method by which a biarylphosphine useful as a Buchwald phosphine ligand can be obtained in high purity is provided through an industrially advantageous process. The production method of a biarylphosphine comprises a step A of reacting a lithiated product obtained through lithiation of a halogenated benzene derivative with a benzene derivative to obtain a biphenyl derivative, and a step B of the reacting the biphenyl derivative with a halogenated phosphine. In the step A, the charge molar ratio of the halogenated benzene derivative to the benzene derivative is preferably 1.0 to 5.0.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: September 27, 2022
    Assignee: NIPPON CHEMICAL INDUSTRIAL CO., LTD.
    Inventors: Ken Tamura, Yuki Sawatsugawa, Natsuhiro Sano
  • Patent number: 11446279
    Abstract: Aspects of the present disclosure include antibacterial aromatic sulfonyl fluoride agents. The subject aromatic sulfonyl fluoride agents have a pharmacophore that can provide for potent antibacterial activity. The subject agents are compounds including an aromatic group substituted with a sulfonyl fluoride warhead group and an electron withdrawing group. The subject agents find use in a variety of antibiotic applications. In some cases, the subject agents find use in methods of treating bacterial infections in a subject. Also provided are pharmaceutical compositions and kits that find use in practicing the subject methods.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 20, 2022
    Assignee: The Regents of the University of California
    Inventors: Niren Murthy, Corinne Sadlowski, Bora Park
  • Patent number: 11447437
    Abstract: An organic compound is represented by formula (1). In the formula (1), R1 to R24 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryloxy group, a silyl group, and a cyano group.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: September 20, 2022
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yosuke Nishide, Naoki Yamada, Jun Kamatani
  • Patent number: 11419335
    Abstract: The present invention provides novel compounds of Formula (I?) and (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for killing a microorganism (e.g., bacteria, fungi, viruses, protozoa, or multicellular parasites), the prevention and/or treatment of infectious diseases (e.g., infections by microorganisms, bacterial infection, cystic fibrosis infection, foreign body infection, urinary tract infection (UTI), or infections leading to biofilms), controlling and/or eradicating biofilms (e.g., bacterial biofilms), preventing biofilm formation, sterilizing a surface, and/or eradicating persister cells (e.g., in a subject in need thereof or in a subject involving a biofilm).
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 23, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Robert William Huigens, III, Yasmeen Abouelhassan, Akash Basak
  • Patent number: 11414594
    Abstract: A low dimerizing electrochromic compound for use in electrochromic mediums and electro-optic elements incorporating said electrochromic mediums is provided. The low dimerizing electrochromic compound is represented by Formula (I): wherein each R1 is individually an alkyl, a hydroxyalkyl, or an alkyl substituted with at least one polymerizable functional group; each R2 is a hydrogen; each R3 is individually a hydrogen or an alkyl; and each R4 is individually a hydrogen, an alkyl, or a hydroxyalkyl; and X? is an anion.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 16, 2022
    Assignee: GENTEX CORPORATION
    Inventors: Leroy J. Kloeppner, Zachary B. Erno, Henry A. Luten
  • Patent number: 11414443
    Abstract: The present invention relates to 1-acyl-lysophosphatidyl derivatives of general formula I; in which R is C4 to C30 aliphatic hydrocarbyl chain, R1 is selected from H or C1 to C10 alkyl, preferably C1 to C6 alkyl, R2 is selected from H, C10 to C30 acyl or C1 to C10 alkyl, preferably C1 to C6 alkyl, and R3, when present, is selected from H or C1 to C10 alkyl, preferably C1 to C6 alkyl. These derivatives are intended for the treatment of cancer, in particular melanoma, hepatocarcinoma or GIT carcinomas.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: August 16, 2022
    Assignees: USTAV MOLEKULARNI GENETIKY AV CR, V.V.I., SMART BRAIN S.R.O.
    Inventors: Michal Dvorak, Marta Dvorakova, Vit Karafiat, Jan Stursa, Lukas Werner, Lucie Janeckova
  • Patent number: 11413255
    Abstract: Methods, filters and compositions are disclosed for treating toxicity due to oxidative stress and toxic electrophiles.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: August 16, 2022
    Assignee: Montefiore Medical Center
    Inventors: Richard M. LoPachin, Terrence Gavin, Brian Geohagen
  • Patent number: 11414439
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: August 16, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alexander Russell Abela, Jeremy J. Clemens, Peter Diederik Jan Grootenhuis, Sara Sabina Hadida Ruah, Yoshihiro Ishihara, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Fabrice Jean Denis Pierre, Joe Anh Tran, Jinglan Zhou
  • Patent number: 11407704
    Abstract: Provided is an improved process of vitamin K2 derivatives preparation, represented by formula (I) wherein n is an integer from 3 to 13.
    Type: Grant
    Filed: April 6, 2019
    Date of Patent: August 9, 2022
    Assignee: Siec Badawcza Lukasiewicz-Instytut Chemii Przemyslowej imienia Profesora Ignacego Moscickiego
    Inventors: Katarzyna Sidoryk, Marek Napiorkowski, Agnieszka Burzynska-Prajzner, Marcin Cybulski, Marek Kubiszewski, Kamil Jatczak, Lukasz Jedynak, Jerzy Winiarski, Dorota Pietrzkowska, Konrad Zielinski
  • Patent number: 11407726
    Abstract: This invention relates generally to the synthesis of E-macrocycles using stereoretentive ruthenium olefin metathesis catalysts supported by dithioiate ligands. Macrocycles were generated with excellent selectivity (>99% E) and in moderate to high/good yields (47% to 80% yield; 58% to 80% yield) from diene starting materials bearing two E-olefins or bearing one E-olefin and one terminal olefin, A variety of rings were constructed, ranging from 12- to 18-membered macrocycles, including the antibiotic recifeiolide. The invention has utility in the fields of organometallics and organic synthesis.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: August 9, 2022
    Assignee: California Institute of Technology
    Inventors: Tonia S. Ahmed, T. Patrick Montgomery, Robert H. Grubbs
  • Patent number: 11400160
    Abstract: The present invention provides compounds suitable for use in the treatment of conditions where it is beneficial to halt bone loss and kill cancer cells, particularly in metastases to and primary tumours in the bone and surrounding tissues. Consequently the present invention provides compounds comprising a bisphosphonate moiety linked to a phytochemical, pharmaceutical compositions thereof and methods of treatment of bone diseases and/or proliferative disorders.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 2, 2022
    Assignee: E.P.O.S IASIS Research and Development Limited
    Inventors: Andreani Odysseos, Andreas Evdokiou, Anastasios Keramidas
  • Patent number: 11401253
    Abstract: 16-membered macrolide compounds inhibit growth of various microbial species and have utility in the treatment of systemic or topical microbial infections, including methicillin-resistant strains (Formula I).
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 2, 2022
    Assignee: THE UNIVERSITY OF MONTANA
    Inventors: Andrea Stierle, Donald Stierle, Nigel Priestley
  • Patent number: 11396453
    Abstract: The present invention relates to a metal phase transformation compound and a method for preparing the same.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: July 26, 2022
    Assignee: WEBIOTREE CO.. LTD
    Inventors: Ho Jun Kim, Ki Yeok Kim
  • Patent number: 11396512
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Patent number: 11396509
    Abstract: The present disclosure provides solid forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: July 26, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Sylvie M. Asselin, Henry G. Morrison
  • Patent number: 11390752
    Abstract: Provided is a coloring composition capable of forming a cured film having desired spectral characteristics even for thin-film. In addition, provided are a cured film, a pattern forming method, a color filter, a solid-state imaging element, and an image display device. The coloring composition contains: a pigment A having a structure in which an aromatic ring group into which a group with an oxygen atom, a sulfur atom, or a nitrogen atom bonded to an aromatic ring is introduced is bonded to a diketopyrrolopyrrole skeleton; and a compound having a curable group. A content of the pigment A in a total solid content of the coloring composition is 40% by mass or more.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: July 19, 2022
    Assignee: FUJIFILM Corporation
    Inventors: Akio Mizuno, Hidekazu Oohashi, Masahiro Mori, Hiromu Koizumi
  • Patent number: 11389459
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: July 19, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
  • Patent number: 11382984
    Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: July 12, 2022
    Assignee: QUIAPEG PHARMACEUTICALS AB
    Inventor: Marek Kwiatkowski
  • Patent number: 11384102
    Abstract: The invention relates to lithium alkyl aluminates according to the general formula Li[AlR4] and to a method for preparing same, starting from LiAlH4 and RLi in an aprotic solvent. The invention also relates to compounds according to the general formula Li[AlR4] which can be obtained using the claimed method, and to the use thereof. The invention also relates to the use of a lithium alkyl aluminate Li[AlR4] as a transfer reagent for transferring at least one radical R to an element halide or metal halide and to a method for transferring at least one radical R to a compound E(X)q for preparing a compound according to the general formula E(X)q-pRp, where E=aluminium, gallium, indium, thallium, germanium, tin, lead, antimony, bismuth, zinc, cadmium, mercury, or phosphorus, X=halogen, q=2, 3 or 4, and p=1, 2, 3 or 4. The invention also relates to compounds which can be obtained using such a method, to the use thereof, and to a substrate which has an aluminium layer or a layer containing aluminium on one surface.
    Type: Grant
    Filed: November 28, 2019
    Date of Patent: July 12, 2022
    Assignee: Umicore AG & Co. KG
    Inventors: Susanne Herritsch, Joerg Sundermeyer